LAIs Tied to Lower Relapse, Mortality Risk in Schizophrenia
Oct 16, 2025 · Long-acting injectable antipsychotics are linked to a lower risk for disease relapse and mortality than oral antipsychotics in adults with schizophrenia, a new study shows.
Metoclopramide in the Treatment of Diabetic Gastroparesis
Acute Dystonic Reactions Acute dystonic reactions are the most frequent extrapyramidal side effects (EPS) from metoclopramide and typically occur within 24–48 h of initiating treatment, thus ...
Forget the Tremor: These Symptoms Come First in Parkinson’s
Jun 10, 2025 · It often appears alongside other signs like a softer, monotone voice or reduced arm swing while walking — both early signs of extrapyramidal dysfunction.
Treatment Considerations for Psychiatric Syndromes Associated with …
Another important consideration is HIV-infected patients' increased sensitivity to antipsychotic-induced extrapyramidal symptoms, thought to be related to the damage to basal ganglia observed in ...
FDA OKs First-in-Class Antipsychotic for Schizophrenia
Sep 27, 2024 · The FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.
Depression, Extrapyramidal Symptoms, Dementia and an ... - Medscape
A patient symptoms of functional and cognitive decline, dyskinesia and depression surprisingly resolve after a suicide attempt.
Ending Long-term Anticholinergic Use: It Can Be Done - Medscape
Jun 3, 2020 · Ending the common, but unsanctioned, practice of long-term anticholinergic use to head off extrapyramidal symptoms (EPS) associated with antipsychotic medications in patients with …
Untreated Tardive Dyskinesia Hinders Use of Antipsychotics
Jul 29, 2024 · Tardive dyskinesia, often underdiagnosed and undertreated, hinders patient adherence to antipsychotics, affecting mental health treatment and caregivers' well-being, reports Dr Daniel …
Olanzapine Associated With Lower Rate of Extrapyramidal ... - Medscape
Oct. 2, 2003 — Olanzapine was associated with the fewest patients with extrapyramidal symptoms (EPS) at six months compared with baseline, according to the results of a large prospective trial ...
Positive Phase 3 Results for Antipsychotic in Schizophrenia
Jan 12, 2024 · The investigational antipsychotic KarXT is effective in reducing positive and negative symptoms of schizophrenia, with a favorable side-effect profile in the pivotal EMERGENT-2 trial.